Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
As at 2022-12-31 |
As at 2021-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification |
GenSight Biologics
|
— | — |
| Length of life of limited life entity |
We were incorporated on April 17, 2012.
|
— | — |
| Statement of IFRS compliance [text block] |
This Universal Registration Document includes our annual consolidated financial statements prepared in accordance with IFRS as adopted by the European Union as of and for the fiscal year ended December 31, 2022 presented in this Universal Registration Document in Section 18.1.1, “Company’s Annual Consolidated Financial Statements (IFRS) for the Fiscal Year Ending December 31, 2022.”
|
— | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current trade receivables | — |
0
EUR
|
754,000
EUR
|
| Current trade payables | — |
7,813,000
EUR
|
11,561,000
EUR
|